Gritstone bio up on promising data from COVID-19 vaccine study

Gritstone bio

25/10/2022 16:39

** Drug developer Gritstone bio Inc's shares  GRTS.O  rise
5.1% to $2.38 
    ** Co says early-stage study of its experimental vaccine to
treat COVID-19 showed tolerability and immunogenicity across
several subject populations  urn:newsml:reuters.com:*:nGNXc45LJD
    ** Co also announced agreement to sell stock through a
private investment to raise a proceed of $45 mln  urn:newsml:reuters.com:*:nGNX9cNJ0k
    ** Including session gains, stock had fallen 82% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))